 |
인쇄하기
취소
|
Korea Meditech exclusively to distribute an anti-allergic drug.
Vice president Kim Yeon-pan of Korea Meditech Co. made an exclusive distribution agreement for Oralgen, a novel anti-allergic drug, with Fornix Biosciences of Netherland on July 12.
Oralgen is a new immuno-therapeutic agent for various allergic disorders caused by an environmental pollution including air and pollen as a sublingual dosage form, and sold widely across the European countries.
Oralgen is a new immuno-therapeutic agent for various allergic disorders caused by an environmental pollution including air and pollen as a sublingual dosage form, and sold widely across the European countries.
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.